ascopubs.org

Use of liposome encapsulated doxorubicin citrate (LEDC) as a valid drug in patients affected by ovarian cancer suffering from chemotherapy side-effects.

ADXS11-011 immunotherapy: Preliminary safety data from two P2 studies in women with CIN 2/3 and with recurrent/refractory cervical cancer. This is an ASCO Meeting Abstract from the 2012 ASCO Annual ...
Monthly Prescribing Reference

Doxorubicin Hcl

Doxorubicin HCl 10mg/vial, 20mg/vial, 50mg/vial; pwd for IV inj after reconstitution; contains lactose. Risk of cardiomyopathy (including left ventricular failure), arrhythmias. Pre-existing heart ...
ascopubs.org

Nursing support program to decrease or prevent side effects of pegylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (REOC)

Subcutaneous administration of cefepime: An option when the IV route is problematic No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2005 ASCO Annual ...
MedPage Today

Long-Term Breast Cancer Risk in Hodgkin Lymphoma Survivors Treated With Doxorubicin

A common chemotherapy drug used to treat Hodgkin lymphoma conferred a significantly increased risk of breast cancer among women treated during adolescence and adulthood, a large retrospective study ...
WRIC

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend ...